A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...
GlobalData on MSN
Telix doses first patient in TLX591-Px prostate imaging trial
Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation ...
An electronic health record-integrated AI agent developed to improve patient education on prostate cancer with personalized ...
MedPage Today on MSN
'Most compelling' data yet for metastasis-directed therapy in prostate cancer
But an association with improved overall survival failed to reach statistical significance ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
What key experiences or clinical gaps motivated your focus on advancing prostate cancer diagnostics, particularly MRI-led ...
As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...
An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results